PT-141: The First FDA-Approved Peptide for Sexual Health

Bremelanotide (PT 141, marketed as Vyleesi) represents a fundamentally different approach to sexual health pharmacotherapy. While PDE5 inhibitors (sildenafil, tadalafil) work peripherally on vascular smooth muscle to enhance erectile function, bremelanotide acts centrally, in the brain, through melanocortin receptors to increase sexual desire. This distinction is critical: bremelanotide treats the "wanting," while PDE5 inhibitors treat the "functioning." They address different components of the sexual response cycle (Kingsberg et al., 2019, Obstetrics & Gynecology; PMID: 31135726).

The melanocortin system is a neuroendocrine signaling network involving five receptor subtypes (MC1R through MC5R) and their peptide ligands, primarily alpha melanocyte stimulating hormone (alpha MSH) and related peptides derived from proopiomelanocortin (POMC). This system regulates diverse functions including pigmentation (MC1R), adrenal function (MC2R), energy balance and appetite (MC3R and MC4R), and exocrine function (MC5R). Sexual desire is regulated in part through MC4R signaling in the hypothalamus and limbic system. Activation of MC4R in these brain regions promotes sexual arousal and desire through downstream effects on oxytocin and dopaminergic pathways. The discovery that MC4R activation could enhance sexual function was actually serendipitous. Researchers studying melanotan II (a tanning peptide) for skin pigmentation noticed that trial participants reported spontaneous sexual arousal as a side effect (Hadley, 2005, Peptides; PMID: 15911072).

Melanotan II is a nonselective melanocortin agonist that activates multiple MC receptor subtypes, producing effects including skin tanning, appetite suppression, and sexual arousal. However, its nonselective binding raised safety concerns, particularly regarding cardiovascular effects. Bremelanotide was developed as a more targeted cyclic heptapeptide analogue with preferential activity at MC1R and MC4R. By narrowing the receptor binding profile, developers aimed to retain the sexual function benefits while improving the safety profile. After an initial intranasal formulation was abandoned due to blood pressure concerns, the subcutaneous route was adopted, which demonstrated both efficacy and improved tolerability.

Bremelanotide's FDA approval was based on two pivotal Phase III trials, RECONNECT 1 and RECONNECT 2, in premenopausal women with hypoactive sexual desire disorder (HSDD). On the primary endpoint, change from baseline in the Female Sexual Function Index desire domain score, bremelanotide produced statistically significant improvements over placebo (+0.5 points, p < 0.001). It also significantly reduced distress related to low sexual desire as measured by the Female Sexual Distress Scale. Approximately 25% of women treated with bremelanotide reported meaningful improvement in desire, compared to 17% with placebo. That is a modest but statistically significant difference. It is important to set realistic expectations: bremelanotide is not a "magic switch" for desire. It produces a meaningful improvement in a subset of patients, which is consistent with the complexity of sexual desire as a biopsychosocial phenomenon.

While bremelanotide is FDA approved only for premenopausal women with HSDD, off label use in men is common in clinical practice. The physiological rationale is sound, as MC4R mediated sexual arousal pathways are present in both sexes. Preliminary studies and clinical experience suggest efficacy for male sexual dysfunction, particularly in cases where PDE5 inhibitors are insufficient or contraindicated, and in men with low desire rather than erectile dysfunction specifically. Typical off label dosing in men is 1 to 2 mg subcutaneously, administered 30 to 60 minutes before anticipated sexual activity. As with the FDA approved indication, this is on demand use rather than daily dosing.

The most common side effects include nausea (about 40% incidence, usually mild to moderate, often diminishing with repeated use; taking an antiemetic 30 minutes before injection can help), flushing (about 20%, related to melanocortin mediated vasodilation), injection site reactions (about 13%), headache (about 11%), and transient skin darkening with repeated use due to MC1R activation (more common with melanotan II but possible with bremelanotide, particularly in patients with darker skin types or moles). Bremelanotide can cause a transient, small increase in blood pressure (average 2 to 3 mmHg systolic) and decrease in heart rate, so it is not recommended in patients with uncontrolled hypertension or cardiovascular disease. The FDA label limits use to no more than once every 24 hours and no more than 8 doses per month. It should not be used concurrently with naltrexone due to reduced efficacy of both drugs, and caution is advised with medications that slow gastric emptying.

Bremelanotide is available as a 1.75 mg/0.3 mL prefilled autoinjector (Vyleesi). It is self administered subcutaneously in the abdomen or thigh, at least 45 minutes before anticipated sexual activity, with a maximum of 1 dose per 24 hours and 8 doses per month. Providers should set realistic expectations, discuss that approximately 1 in 4 women report meaningful improvement, consider a trial of 8 doses before assessing efficacy, and counsel about nausea with antiemetic guidance.

Bremelanotide's approval represents an important milestone: recognition that sexual desire is a legitimate medical concern with neurobiological underpinnings that can be therapeutically targeted. Its central mechanism, working through brain circuits that regulate desire rather than peripheral vascular function, opens a conceptually different approach to sexual health pharmacotherapy. While not a cure all, it provides a genuinely novel option for patients whose primary concern is desire rather than physical arousal or function.